General Rheumatology
Bella Mehta bella_mehta
3 months ago
Many GLP-1 drugs in the pipeline for management in #OA
#ACR25 @rheumnow https://t.co/y3UCp0CcUb
Bella Mehta bella_mehta
3 months ago
Semaglitide did help in weight loss and decrease in pain in knee OA
https://t.co/240sR5An3m
#acr25 @rheumnow
Question is that is the pain decrease is secondary to weight loss or an independent effect? https://t.co/R2v5YDP3A5
Md Yuzaiful Md Yusof Yuz6Yusof
3 months ago
#ACR25 Abstr#1535 This is super-cool & watch this space! Novel Bi-specific T-cell Engager using pan-gamma delta TCR instead of currently used CD3. In vitro study = complete B-cell depletion comparable to other BiTE, but with a more favorable cytokine release profile @RheumNow https://t.co/PtR5g3gCPH
Bella Mehta bella_mehta
3 months ago
List of GLP1 agonists approved currently..would they have effects in #OA
Session title is should we gave them to everyone?
#ACR25 @RheumNow https://t.co/dXwB6Jkg8C
Janet Pope Janetbirdope
3 months ago
HOPE for Pts w #fibromyalgia #FM
#Transcutaneous #electrical #nerve #stimulation + #physio
Is
Better than #PT alone
#Pragmatic #cluster #randomized #trial
Answered impt question
Does #TENS help Pts w #fibro
Too ba noTENS sham
Abst#LB03 #ACR25 #ACRBest @RheumNow @ACRheum https://t.co/fGyAugFtcN
Dr. John Cush RheumNow
3 months ago
REPLENISH - Secukinumab Works in Polymyalgia Rheumatica
Novartis announced the results of their REPLENISH trial showing the efficacy of secukinumab (Cosentyx) (SEC) in adults with polymyalgia rheumatica (PMR).
https://t.co/CLmCdBXiOf https://t.co/z20nWd2NSM
Nouf Al hemmadi NoufAhmedAlham2
3 months ago
Next Generation T-Cell Engager: The Future https://t.co/gcrfzV6MSJ via @YouTube
@alhkim great to see you and hearing all about new T cell Engager , feasibility and less toxicity.
@RheumNow
#ACR25
Mrinalini Dey DrMiniDey
3 months ago
#0852 LEVI-04, a novel p75NTR-Fc fusion protein, significantly reduces MRI bone marrow lesions in knee #OA 🦵📉
Phase II RCT (n=518): dose-dependent BML reduction (p<0.001) + correlated improvement in pain & function. Promising structure-modifying OA therapy
@RheumNow #ACR25 https://t.co/huA8OaFGSd
sheila RHEUMarampa
3 months ago
In this ph2 trial of LEVI-04 for knee #osteoarthritis,
At wk 20, LEVI-04 ⬇️ bone marrow lesions (BML), greater ⬇️ in BML area even w/ higher KL grades
Promising treatment.
#ACR25 @RheumNow Abs0852 #ACRBest https://t.co/MrmLPlFiDs
Gabriela Martinez Zayas, MD MartinezZayasMd
3 months ago
Summary take home points by Dr Highland
1. PAH and PH-ILD are associated with high mortality in patients with SARDs
2. Multimodal and early screening is recommended
3. “It takes a village” work with Pulm and Cardiology colleagues
@RheumNow #ACR2025 https://t.co/Xa7TecMOIe
David Liew drdavidliew
3 months ago
In the #ACR25 Great AI Debate, @RADoctor and @JYazdanyMD prepared independently, but in consecutive moments agree (in a very illustrative way):
guardrails - they need to happen
@RheumNow https://t.co/ccLLC3adxG
Janet Pope Janetbirdope
3 months ago
What is better in #PsA post #TNFi?
#RCT of #secukinumab v #ustekinumab
The big 🤔? #IL17Ai vs IL12/23i
🏆 #Cosentyx
✈️✅PASI
⚜️✅ACR50
Will H2H studies change our #prescribing?🤷♀️
#rheums Rx #IL17i>#IL12i/23i vs #derms
#ACRBest #ACR25 @RheumNow @ACRheum abst#LB06 https://t.co/RpC8ymDc7H
Dr. John Cush RheumNow
3 months ago
🎥 LIVE from #ACR25
Join us daily at 5 PM CST for RheumNow’s ACR Recap Live -
Your must-watch debrief of the day’s biggest breakthroughs, hot abstracts, and real-time clinical takeaways.
Streaming on YouTube Live, Facebook Live, X-Live & LinkedIn Live.
Save the time. Be part of https://t.co/xn4yUta9Da
As the population ages globally, rheumatologists are caring for an increasingly older patient population more than ever before. In RA alone, nearly 40 percent of patients are now aged 65 years or older. Yet the evidence guiding our treatment decisions continues to come from studies that rarely include them, giving rise to a fundamental question: do we really know how best to treat older adults with rheumatic diseases?
Poster Hall